Core Insights - ZyVersa Therapeutics, Inc. is advancing a pipeline of first-in-class drug candidates targeting inflammatory and renal diseases with high unmet medical needs [3][5] - The company is developing two key drug candidates: Inflammasome ASC Inhibitor IC 100 for obesity with metabolic complications and Cholesterol Efflux Mediator VAR 200 for diabetic kidney disease [1][2][5] - The total accessible market for ZyVersa's therapeutic areas exceeds $100 billion, indicating significant growth potential [5] Drug Candidates - Inflammasome ASC Inhibitor IC 100 is designed to reduce disease-causing inflammation, with a lead indication for obesity-related metabolic complications [1][5] - Cholesterol Efflux Mediator VAR 200 aims to facilitate the removal of renal lipids and cholesterol, with a phase 2a clinical trial in diabetic kidney disease expected to commence in Q1-2025 [2][5] Corporate Engagement - Stephen C. Glover, the Co-Founder and CEO, will attend the JPM 43rd Annual Healthcare Conference in January 2025 to discuss ZyVersa's technology and development milestones [3][4] - The company is open to one-on-one meetings with industry strategics and investors to explore value-building opportunities [4]
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco